This episode features a powerful discussion on evangelism and street ministry, sharing real-life testimonies of how simple acts of love and obedience can lead to profound spiritual encounters. Learn practical tips, the importance of follow-up, and how to cultivate a heart for evangelism in everyday life.Chapters00:00 Introduction to Evangelism Training02:06 Experiencing Evangelism in Action11:48 Building Relationships Through Prayer22:10 Divine Appointments and God’s Guidance27:31 The Importance of Commitment and Obedience

In this episode of AWM Insights, Justin Dyer and Mena Hanna tackle the complexities of artificial intelligence and its sweeping influence on both public and private markets. They break down the hype, explore the shifting fortunes of major sectors, and share lessons from history on market concentration, bubbles, and the power of diversification. With a clear focus on long-term, generational wealth, Justin and Mena offer perspective and strategy for families seeking to navigate today’s dynamic investment landscape. Tune in to hear seasoned insights on avoiding costly missteps and investing like a pro in an era defined by creative destruction.Chapters(00:00) Setting the Stage for AI in Markets(01:36) Public Market Impacts and Major Headlines(03:23) Market Efficiency and the Challenge of Timing(04:52) Lessons from Historical Market Concentrations(06:26) The Power of Diversification(11:50) True Diversification and Private Market Access(13:33) Key Takeaways for the 100-Year FamilyConnect with Us• Call or text us: 626-862-0355• Website: https://www.athletefamilyoffice.com/• YouTube: https://www.youtube.com/channel/UCc1NxpK21N1vKWEExC45YEA• LinkedIn: https://www.linkedin.com/company/awmcapital/• Instagram: https://www.instagram.com/awmcapital/• X: https://twitter.com/awmcapital• Facebook: https://www.facebook.com/awmcapital/

Small bay industrial flex space has held under 3% vacancy nationwide for three consecutive years. Some major markets have no available inventory at all. One of AAA's Texas projects delivered a 1,300% IRR. And most commercial real estate investors have never even heard of this asset class. If you are an accredited investor looking for where serious capital is moving in 2026, this episode is for you. Paul Bennett, who has been developing small bay industrial since 2011, answers the nine questions investors are asking right now: what this asset class actually is, why supply is structurally constrained, how AAA underwrites to a 10.5% yield on cost, why a $12M project can stabilize at $21M in value, how triple net leases protect investors from rising property taxes and insurance, and how small bay pairs with self-storage inside Growth Fund 2 to give investors diversification across two product types and four markets in a single investment. Next episode: AAA's Shawn Beichler walks through design, construction, and lease-up on a live project. Ready to talk about your investment strategy? Reach out at aaastorageinvestments.com New episodes every two weeks. Subscribe on Apple Podcasts, Spotify, or wherever you listen to podcasts, and send this to an investor in your network who needs to hear it. Chapters(00:00) Why Small Bay Industrial Is Outperforming Every Asset Class Right Now (01:00) What Industrial Flex Actually Is and Who Leases It (03:10) Sub-3% Vacancy and Critically Low Inventory in Major Markets (06:30) Why a $12M Project Is Worth $21M at Stabilization (09:00) How Triple Net Leases Protect Investors From Rising Costs (12:00) Why This Tenant Base Is More Recession-Resilient Than You Think (18:57) AAA's Turnkey Build-Out Model and Why It Fills Space Faster (25:04) How Self-Storage and Small Bay Work Together in Fund 2We believe good investing starts with a conversation, so if today's episode got you thinking about your investment strategy, reach out to us through our Contact Form and let's start building together: https://www.aaastorageinvestments.com/contactFollow and Connect with Us• LinkedIn: https://www.linkedin.com/company/aaa-storage-investments/• Instagram: https://www.instagram.com/aaastorageinvestments/• X: https://x.com/investments_aaa• Facebook: https://www.facebook.com/people/AAA-Storage-Investments-LLC/61575027573292/Download our free guides to take your investing to the next level:10 Due Diligence Questions to Vet Any Real Estate Sponsor: https://www.aaastorageinvestments.com/info/10-due-diligence-questions-to-vet-any-real-estate-sponsorFirst-Time Real Estate Syndication Investor Checklist: https://www.aaastorageinvestments.com/info/first-time-real-estate-syndication-investor-checklist

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Nick Berry investigate how futility in clinical trials and stopping rules in sports illuminate very similar decision problems, albeit with very different consequences. Drawing from baseball’s 10-run rule, tournament cuts in golf, the discussion confronts traditional and Bayesian strategies for interim decisions. The episode explains why simulation, not historical trial review, provides the empirical backbone for futility boundaries in clinical trials, and details the mechanics and consequences of aggressive stopping criteria. Using the Biogen aducanumab Alzheimer’s trials, the conversation exposes how a futility rule based on 20% predictive probability halted trials even when meaningful probability of success remained. Scott and Nick address the influence of ethical considerations, cost, regulatory priorities, and statistical rigor, and contrast Bayesian predictive probability’s strengths over conditional power.Key HighlightsDissects sports futility rules (10-run rule, golf cuts, Bill James heuristic) and their application to clinical trial designArgues for prospective simulation to define adaptive futility thresholdsExplains how Bayesian predictive probability provides a more robust framework than conditional probability for interim adaptive decisionsDetails how aggressive futility criteria may prematurely stop trials and risk missing beneficial treatments, as in the aducanumab caseExplores the intersection of ethics, patient safety, operational efficiency, regulatory standards, and trial cost